Fear of higher interest rates struck with a vengeance on September 9, as the nearly 400-point decline in the Dow Jones Industrial Average demonstrated. Stocks fell hard and with purpose in response to comments from Boston Fed governor Erik Rosengren, who said he supported higher interest rates, albeit at a… Read More
Dr. Joe Duarte is Chief Investment Strategist and Editor of Profit Catalyst Alert and Weekly Cash Machine. He has been a professional investor and independent analyst since 1990. He is a former Registered Investment Advisor and author of the Bestselling "Options Trading for Dummies," now in its 4th edition and several other books including "Market Timing for Dummies" and "Successful Biotech Investing". Although Joe's favorite areas of the market are technology and healthcare, he is a versatile investor who enjoys finding that hidden gem stock before the crowd, no matter what the sector. He is an original CNBC Market Maven, and is visible regularly on Stockcharts.TV. He has published articles on Marketwatch.com and has been widely quoted in the major media including The Wall Street Journal and Barron’s magazine.
Analyst Articles
Investors may have some big decisions to make in the next few days as the stock market reacts to an increasingly likely rate hike from the Fed, perhaps as soon as next week. So, in this column, let’s take a look at the stock market and identify the major reason why… Read More
As we head into the home stretch for the U.S. presidential election, and the often unpredictable months of September and October, it’s important to closely monitor our portfolios. The global economy continues to show signs of sluggishness and the financial markets are becoming increasingly unpredictable due to potential central bank… Read More
I am recommending the purchase of put options on Anthem Inc. (NYSE: ANTM), a leading U.S. health insurer which offers Blue Cross/Blue Shield plans in fourteen states. The company’s shares have been slowly falling of late and are reaching an attractive price area for this strategy. I’ll tell you why… Read More
I have been increasingly concerned about the action in the overall stock market for some time, and the action on yesterday (8/24) afternoon and this morning suggested that it’s time to buy some portfolio protection. So I am recommending the purchase of the ProShares Ultrashort ETF (BIS) as a hedge for a diversified… Read More
Today, I am (1) closing out a bonus position I recommended earlier this year in Celldex Therapeutics (Nasdaq: CLDX); (2) increasing the buy limit on my latest pick Diebold Nixdorf (NYSE: DBD); and, (3) changing my rating on Ambarella (Nasdaq: AMBA) to ‘Hold’. I explain the rationale for these moves in… Read More
- August 18, 2016
-
Download Issue
Diebold is buying its way into global growth and new businesses. Read More
I am raising the rating on Medidata Solutions (NSDQ: MDSO), the leading cloud based software platform for biotech research management to Buy from Hold. I recommended the stock in March 2015 and so far it has delivered a 51% price increase. But recent price behavior suggests that it’s poised for… Read More
In my most recent Technical Nuggets column, (August 1, 2016) I noted: “Lower interest rates have created momentum conditions where higher prices continue to bring in buyers. This momentum dynamic has pushed this bull market much further than anyone could have expected and the current trend remains up but… Read More
Seres Therapeutics (Nasdaq: MCRB), a research stage biotech company seeking to use the human microbiome to treat gut-related illnesses, expanded its losses in its most recent quarter. The company reported a loss of $27.8 million, or 70 cents per share, and $3 million in revenues for the quarter as it… Read More